Limited Competition: Transformative Research to Address Health Disparities and Advance Health Equity at Minority Serving Institutions (U01 Clinical Trial Optional) | RFA RM 22 001

FAQs: NIH Limited Competition U01 for Transformative Health Disparities and Health Equity Research at MSIs (RFA-RM-22-001)

What is this funding opportunity?

This is an NIH funding opportunity titled "Limited Competition: Transformative Research to Address Health Disparities and Advance Health Equity at Minority Serving Institutions (U01 Clinical Trial Optional)" (RFA-RM-22-001; CFDA 93.310). It supports unusually innovative, high-risk, high-reward research intended to meaningfully reduce or eliminate health disparities and advance health equity.

What kind of research is NIH looking for?

The focus is on transformative intervention research that could change how interventions are developed, implemented, or disseminated, especially in areas where standard approaches have not been sufficient. The emphasis is on major impact rather than incremental progress.

What does "transformative" mean in the context of this program?

In this program, "transformative" refers to projects with the potential to create large, durable gains in health equity by introducing novel strategies or approaches. Applications are expected to make a strong case that the work could shift the field, not just modestly improve existing methods.

Is preliminary data required?

No. A key feature of this announcement is that preliminary data are not required. This signals that NIH is intentionally making room for bold ideas supported by strong logic, theory, or compelling rationale rather than extensive prior results.

What is the funding mechanism?

The opportunity uses the U01 cooperative agreement mechanism. This differs from a traditional research project grant because NIH staff are expected to have substantial programmatic involvement during the project.

What does a U01 cooperative agreement imply for project management?

Because this is a cooperative agreement, applicants should be prepared to collaborate with NIH staff on refining milestones, coordinating activities, and maintaining clear progress monitoring throughout the award.

Does the project have to include a clinical trial?

No. The opportunity is designated "clinical trial optional," meaning a project may include a clinical trial but is not required to do so.

If clinical trials are optional, what types of intervention research can be proposed?

Applicants may propose intervention research ranging from early-stage development and testing through implementation and dissemination strategies, as long as the work is positioned to create major impact on health disparities and health equity outcomes.

What outcomes or impact areas should a strong application address?

Projects should clearly explain how the innovation could prevent, reduce, or eliminate disparities and how it advances health equity. Examples of impact areas mentioned include health outcomes, access, quality of care, and related social and structural determinants.

How should applicants frame the need for the proposed approach?

Competitive applications will typically connect the intervention to real-world contexts where disparities arise, explain why current methods are inadequate, and articulate a credible pathway to large-scale change if the approach succeeds.

Is this a limited competition opportunity?

Yes. The announcement is described as a limited competition opportunity with a focus directed at Minority Serving Institutions (MSIs).

Which organizations are eligible to apply?

Eligibility is centered on U.S.-based higher education institutions, including public/state-controlled and private institutions of higher education, with the limited competition focus directed at MSIs.

Which MSI categories are explicitly highlighted as eligible?

The announcement explicitly highlights these eligible MSI categories: Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), and Tribally Controlled Colleges and Universities (TCCUs).

Are foreign (non-U.S.) institutions eligible to apply as the primary applicant?

No. The announcement excludes non-U.S. (foreign) institutions as applicants.

Can non-U.S. components of U.S. organizations apply?

No. The opportunity also excludes non-U.S. components of U.S. organizations from applying.

Are foreign components allowed at all?

Yes. Foreign components, as defined by NIH policy, are allowed. This means a U.S. applicant organization may include certain international elements in the project when scientifically justified and compliant with NIH rules, even though a foreign institution cannot be the primary applicant.

Who is the funding agency?

The funding agency is the National Institutes of Health (NIH).

How is the program categorized?

Administratively, the opportunity is categorized as a discretionary grant program.

What is the original posting date for this opportunity?

The original posting date provided is February 18, 2022.

What is the original closing date for this opportunity?

The original closing date provided is May 23, 2022.

Are the award ceiling and number of expected awards provided?

No. The provided information does not specify an award ceiling or the number of expected awards.

What appears to be the main review priority based on the description?

Based on the framing provided, the central priorities are the strength of the conceptual approach, the novelty of the strategy, and the potential payoff in producing major and durable gains in health equity, rather than incremental advances supported by extensive preliminary data.

What is the overall goal of this NIH initiative?

The initiative is best understood as an NIH effort to catalyze breakthrough intervention research rooted in MSI environments and leadership, prioritizing novel strategies with a plausible, well-argued chance to produce major reductions in health disparities and meaningful advances in health equity.